This study developed and compared several prediction models for pCR after neoadjuvant chemotherapy in patients with HER2-negative BC, using clinical predictors and the molecular biomarkers ER, PgR, and Ki-67 assessed by IHC during routine clinical work. This evidence concerns the gene ERBB2 and breast cancer.